Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
Caron NS, Byrne LM, Lemarié FL, Bone JN, Aly AE, Ko S, Anderson C, Casal LL, Hill AM, Hawellek DJ, McColgan P, Wild EJ, Leavitt BR, Hayden MR. Caron NS, et al. Among authors: leavitt br. Transl Neurodegener. 2024 Oct 8;13(1):50. doi: 10.1186/s40035-024-00443-8. Transl Neurodegener. 2024. PMID: 39380076 Free PMC article.
Towards Standardizing Nomenclature in Huntington's Disease Research.
DiFiglia M, Leavitt BR, Macdonald D, Thompson LM; Huntington’s Disease Nomenclature Working Group:. DiFiglia M, et al. Among authors: leavitt br. J Huntingtons Dis. 2024;13(2):119-131. doi: 10.3233/JHD-240044. J Huntingtons Dis. 2024. PMID: 38968054 Free PMC article. Review.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Among authors: leavitt br. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS, Aly AE, Findlay Black H, Martin DDO, Schmidt ME, Ko S, Anderson C, Harvey EM, Casal LL, Anderson LM, Rahavi SMR, Reid GSD, Oda MN, Stanimirovic D, Abulrob A, McBride JL, Leavitt BR, Hayden MR. Caron NS, et al. Among authors: leavitt br. J Control Release. 2024 Mar;367:27-44. doi: 10.1016/j.jconrel.2024.01.011. Epub 2024 Jan 24. J Control Release. 2024. PMID: 38215984 Free article.
Tominersen in Adults with Manifest Huntington's Disease.
McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, Zhou J, Schlegel V, Sanwald Ducray P, Hawellek DJ, Dorn J, Simillion C, Lindemann M, Wheelock V, Durr A, Anderson KE, Long JD, Wild EJ, Landwehrmeyer GB, Leavitt BR, Tabrizi SJ, Doody R; GENERATION HD1 Investigators. McColgan P, et al. Among authors: leavitt br. N Engl J Med. 2023 Dec 7;389(23):2203-2205. doi: 10.1056/NEJMc2300400. N Engl J Med. 2023. PMID: 38055260 No abstract available.
Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation.
Aggarwal G, Banerjee S, Jones SA, Benchaar Y, Bélanger J, Sévigny M, Smith DM, Niehoff ML, Pavlack M, de Vera IMS, Petkau TL, Leavitt BR, Ling K, Jafar-Nejad P, Rigo F, Morley JE, Farr SA, Dutchak PA, Sephton CF, Nguyen AD. Aggarwal G, et al. Among authors: leavitt br. J Biol Chem. 2023 Dec;299(12):105475. doi: 10.1016/j.jbc.2023.105475. Epub 2023 Nov 18. J Biol Chem. 2023. PMID: 37981208 Free PMC article.
218 results